Drug class
Bispecific humanised monoclonal antibody; factor VIIIa-mimetic haemostatic biologic
Mechanism of action
Binds activated factor IX (FIXa) and factor X (FX), bringing the two coagulation factors into proximity and mimicking the cofactor function of activated factor VIII (FVIIIa) to support thrombin generation.
General use cases
- Routine prophylaxis to prevent or reduce bleeding episodes in adults and children with haemophilia A (congenital factor VIII deficiency), with or without factor VIII inhibitors; it is not a treatment for acute bleeding episodes
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
